Halozyme (HALO) director reports planned 4,000-share sale; 10b5-1 plan used

Rhea-AI Filing Summary

Bernadette Connaughton, a director of Halozyme Therapeutics (HALO), reported sales of common stock on 09/02/2025 executed under a pre-established Rule 10b5-1 trading plan adopted on 05/29/2025. The Form 4 shows three sell transactions: 100 shares at $71.71, 2,977 shares at a weighted-average $73.618 (range $72.91–$73.89), and 923 shares at a weighted-average $74.111 (range $73.95–$74.38). After these disposals the reporting person beneficially owned 46,952 shares, held directly.

Positive

• Sales were executed under a Rule 10b5-1 trading plan, which provides an affirmative defense and signals pre-planned disposition rather than opportunistic timing
• Filing provides detailed pricing ranges and weighted-average prices, improving transparency about the executed transactions

Negative

• Director reduced direct holdings to 46,952 shares, representing a decrease in insider ownership
• Material number of shares sold (4,000 total) could be interpreted by some investors as insider monetization, though the plan was pre-established

Insights

Financial Analyst

TL;DR: Director sold shares under a 10b5-1 plan; transactions appear pre-planned and routine.

The filing documents orderly sales totaling 4,000 shares (100+2,977+923) executed on 09/02/2025 under a Rule 10b5-1 plan adopted 05/29/2025. Prices reported include a single share at $71.71 and weighted-average prices for two tranches at $73.618 and $74.111, with disclosed ranges for each weighted average. The reporters direct beneficial ownership after the transactions is 46,952 shares. The filing supplies precise price ranges and confirms the 10b5-1 plan, which reduces concerns about opportunistic timing but does not indicate intent or future transactions.

Corporate Governance Expert

TL;DR: Insider sales were executed under a documented trading plan, consistent with governance best practices.

The disclosure indicates the director used a written 10b5-1 trading plan to execute sales on 09/02/2025, which provides affirmative defense to insider trading claims when correctly implemented. The Form 4 includes signer authorization by an attorney-in-fact. Ownership fell to 46,952 shares, and the filer provided weighted-average pricing and ranges for traceability. The filing contains the statutory disclosures required for Section 16 reporting and no amendment flags.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Connaughton Bernadette

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		S(1)		100	D	$71.71	50,852	D
Common Stock	09/02/2025		S(1)		2,977	D	$73.618(2)	47,875	D
Common Stock	09/02/2025		S(1)		923	D	$74.111(3)	46,952	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1.

2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $72.91 to $73.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $73.95 to $74.38. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

	/s/ James Oehler, Attorney-in-Fact	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did HALO director Bernadette Connaughton sell on 09/02/2025?

She sold a total of 4,000 shares of Halozyme common stock in three transactions reported on Form 4 dated 09/02/2025.

Were the sales by the HALO director part of a 10b5-1 trading plan?

Yes. The Form 4 states the sales were made pursuant to a written trading plan adopted on 05/29/2025 in accordance with Rule 10b5-1.

What prices were reported for the shares sold by the HALO director?

The filing reports one sale of 100 shares at $71.71, a tranche of 2,977 shares at a weighted-average $73.618 (range $72.91–$73.89), and 923 shares at a weighted-average $74.111 (range $73.95–$74.38).

How many shares does the reporting person own after these transactions?

After the reported sales the director's direct beneficial ownership is 46,952 shares.

Who signed the Form 4 on behalf of the reporting person?

The Form 4 is signed by James Oehler, Attorney-in-Fact for the reporting person, dated 09/02/2025.